scispace - formally typeset
Search or ask a question
Author

Eliška Krajčovičová

Bio: Eliška Krajčovičová is an academic researcher from Comenius University in Bratislava. The author has contributed to research in topics: Löfgren syndrome & Erythema nodosum. The author has co-authored 1 publications.

Papers
More filters
Journal ArticleDOI
01 Jan 2021-IDCases
TL;DR: In this paper, a case of Lofgren syndrome developing in close temporal association with COVID-19 was reported, which is a rare autoimmune disease that represents an acute form of sarcoidosis.

5 citations


Cited by
More filters
Journal ArticleDOI
TL;DR: This case is unique at the point that vaccine-associated uveitis led to the detection of pulmonary lesions and lymphadenopathy, resulting in clinical and pathological diagnosis of sarcoidosis.
Abstract: A 34-year-old Japanese person with male gender identity who had been taking intramuscular injection of methyltestosterone depot for 11 years after bilateral mastectomy noticed blurred vision 5 days after the second vaccination for COVID-19 (Tozinameran; Pfizer-BioNTech) in the interval of 3 weeks following the first vaccination. The patient was diagnosed as granulomatous iritis with mutton-fat keratic precipitates and small iris nodules at the pupillary margin in the right eye and began to have 0.1% betamethasone eye drops with good response. The patient, however, continued to have fever and malaise and showed a high level of serum soluble interleukin-2 receptor (sIL-2R) even 4 weeks after the second vaccination. Computed tomographic scan disclosed mediastinal and bilateral hilar small lymphadenopathy together with limited granular lesion in the right lung. Gallium-67 scintigraphy demonstrated high uptake not only in mediastinal and hilar lymph nodes but also in bilateral parotid glands. Right parotid gland biopsy revealed noncaseating granulomas and proved pathological diagnosis of sarcoidosis. The systemic symptoms were relieved by oral prednisolone 20 mg daily. Even though the causal relationship remains undetermined, this case is unique at the point that vaccine-associated uveitis led to the detection of pulmonary lesions and lymphadenopathy, resulting in clinical and pathological diagnosis of sarcoidosis. In literature review, 3 patients showed sarcoidosis-like diseases after COVID-19 vaccination: 2 patients were diagnosed clinically as Lofgren syndrome with acute onset of erythema nodosum and ankle swelling, with or without mediastinal and hilar lymphadenopathy, whereas 1 patient with mediastinal lymphadenopathy but no uveitis was diagnosed pathologically by biopsy as sarcoidosis.

11 citations

Journal ArticleDOI
TL;DR: Four patients infected with SARS‐CoV‐2 presenting with symptomatic cardiac sarcoidosis or giant cell myocarditis 1–8 months after mild COVID‐19 are reported, which might suggest that CO VID‐19 could be a trigger for granulomatousMyocarditis.
Abstract: Patients infected with SARS‐CoV‐2 have varying manifestations of cardiac involvement. We report four patients presenting with symptomatic cardiac sarcoidosis (CS) or giant cell myocarditis (GCM) 1–8 months after mild COVID‐19. All patients received immunosuppressive therapy and improved gradually within the following months. The possible temporal association between the CS/GCM and COVID‐19 infection might suggest that COVID‐19 could be a trigger for granulomatous myocarditis.

2 citations

Book ChapterDOI
01 Jan 2023
TL;DR: A broad spectrum of complications following COVID-19 have been documented in adults, including the new onset of autoimmune related manifestations and rheumatic diseases as mentioned in this paper , including rheumatoid arthritis, myositis, antiphospholipid antibodies, ITP, and thyroid dysfunction.
Abstract: A broad spectrum of complications following COVID-19 has been documented in adults, including the new onset of autoimmune-related manifestations and rheumatic diseases. Numerous case studies, reviews, and clinical trials have been published regarding the relationship between COVID-19 and the generation of autoantibodies that may cause rheumatic and autoimmune diseases. The currently suggested pathophysiology that leads to the new onset of such disorders may include well-established mechanisms, such as molecular mimicry and hyperstimulation of the immune system. The prevailing conditions documented following COVID-19 include, yet are not limited to, rheumatoid arthritis, myositis, antiphospholipid antibodies, ITP, and thyroid dysfunction. This chapter will summarize the current documentation of the broad-spectrum rheumatic diseases and autoimmune manifestations mediated by a SARS-CoV-2 infection.
Journal ArticleDOI
TL;DR: A case of sarcoidosis developing after COVID‐19 is presented as an interesting sequela of SARS‐CoV‐2 without complication, suggesting a possible link between the viral infection and dysregulation of the inflammation process.
Abstract: COVID‐19 has been implicated in the development of a range of autoimmune diseases and medical consequences. Sarcoidosis is an inflammatory disease with sustained granulomatous inflammation. The possible main pathogenesis of sarcoidosis is a dysregulation between immune response and certain environmental antigens. We present a case of sarcoidosis as an interesting sequela of COVID‐19. The patient was hospitalized due to SARS‐CoV‐2 without complication. Ten weeks after the illness, his chest computed tomography (CT) showed bilateral hilar, paratracheal and subcarinal lymph node enlargement. Endobronchial ultrasound with transbronchial needle aspiration (EBUS‐TBNA) was performed; pathologic findings were that of well‐formed non‐necrotizing granulomas. Complete eye examination reported panuveitis and papillitis in both eyes. On the basis of these findings, sarcoidosis was diagnosed. Therefore, sarcoidosis developing after COVID‐19 was suggested as a possible link between the viral infection and dysregulation of the inflammation process. However, further studies are needed to confirm this association.
Book ChapterDOI
01 Jan 2023
TL;DR: The long-term impact of the SARS-CoV2 infection on autoimmunity and autoinflammation was investigated in this article , where the authors presented a new approach for shedding new light and unexpected insights on autoimmune/autoinflammatory diseases.
Abstract: The “Severe Acute Respiratory Syndrome-related Coronavirus type 2” (SARS-CoV-2), the infectious agent responsible for the still ongoing “Coronavirus Disease 2019” (COVID-19) pandemic, represents a major environmental trigger and an important piece of the mosaic of autoimmunity and autoinflammation. Several de novo-onset or flares/relapses of autoimmune/autoinflammatory diseases have been reported associated either directly or indirectly with the viral agent. COVID-19 has represented a unique opportunity for shedding new light and unexpected insights on autoimmune/autoinflammatory diseases. These have, in turn, enabled the discovery of novel aspects of the COVID-19 infection, offering already approved, effective and safe drugs, as options to be repurposed in the fight against the novel coronavirus. However, there is still a dearth of information concerning the long-term impact of the virus on autoimmunity and autoinflammation – the so-called long-COVID or postCOVID, which warrants further investigation.